Yoshitaka Miyakawa

Saitama, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 63 publications

Effect of efgartigimod IV on immature platelet fraction in primary immune thrombocytopenia in the ADVANCE IV trial.

Effect of efgartigimod IV on immature platelet fraction in primary immune thrombocytopenia in the ADVANCE IV trial.

Journal: British journal of haematology

Published: June 10, 2026

Rilzabrutinib for persistent or chronic immune thrombocytopenia (ITP): a Bruton tyrosine kinase inhibitor that can target multiple pathophysiological pathways.

Rilzabrutinib for persistent or chronic immune thrombocytopenia (ITP): a Bruton tyrosine kinase inhibitor that can target multiple pathophysiological pathways.

Journal: Expert review of hematology

Published: May 10, 2026

Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial.

Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial.

Journal: American journal of hematology

Published: March 09, 2026

Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real-World International Experience.

Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real-World International Experience.

Journal: American journal of hematology

Published: January 30, 2026

Sutimlimab vs B-cell-targeted therapy in cold agglutinin disease: which is the optimal approach?

Sutimlimab vs B-cell-targeted therapy in cold agglutinin disease: which is the optimal approach?

Journal: Blood

Published: January 16, 2026

Warm Autoimmune Haemolytic Anaemia Management in Asia-Pacific: A Delphi Panel Expert Consensus and Systematic Literature Review.

Warm Autoimmune Haemolytic Anaemia Management in Asia-Pacific: A Delphi Panel Expert Consensus and Systematic Literature Review.

Journal: EJHaem

Published: September 26, 2025

Gene therapy for hemophilia

Gene therapy for hemophilia

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: July 06, 2025

Overview

Overview

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: July 06, 2025

Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases.

Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases.

Journal: Expert review of clinical immunology

Published: April 29, 2025

Effectiveness and safety of ravulizumab for Japanese patients with atypical hemolytic uremic syndrome switched from eculizumab: an analysis of a post-marketing surveillance.

Effectiveness and safety of ravulizumab for Japanese patients with atypical hemolytic uremic syndrome switched from eculizumab: an analysis of a post-marketing surveillance.

Journal: Clinical and experimental nephrology

Published: January 28, 2025

Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study.

Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study.

Journal: Blood

Published: October 17, 2024

Japanese database analysis: effectiveness of early initiation of TPO-RA treatment in tapering corticosteroid dose in ITP.

Japanese database analysis: effectiveness of early initiation of TPO-RA treatment in tapering corticosteroid dose in ITP.

Journal: Blood vessels, thrombosis & hemostasis

Published: September 27, 2024

Showing 1-12 of 63

Last Updated: 09/26/2026